Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Székely E, Hagberg O, Arnljots K, et al. Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. Leuk Lymphoma. 2014;55:1838–1843.
   PubMed Web of Science ®Google Scholar
• Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575–1584.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–3734.
   PubMed Web of Science ®Google Scholar
• Cuttner J, Spiera H, Troy K, et al. Autoimmune disease is a risk factor for the development of non-Hodgkin's lymphoma. J Rheumatol. 2005;32:1884–1887.
   PubMed Web of Science ®Google Scholar
• Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029–4038.
   PubMed Web of Science ®Google Scholar
• Smedby KE, Askling J, Mariette X, et al. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med. 2008;264:514–527.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398–405.
   PubMed Web of Science ®Google Scholar
• Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer. 2009;124:1497–1502.
   PubMed Web of Science ®Google Scholar
• Vanura K, Späth F, Gleiss A, et al. Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis. Ann Hematol. 2011;90:947–954.
   PubMed Web of Science ®Google Scholar
• Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-hodgkin lymphoma subtypes: the interlymph non-hodgkin lymphoma subtypes project. JNCI Monogr. 2014;2014:130–144.
   Google Scholar
• Wang SS, Vajdic CM, Linet MS, et al. Associations of non-hodgkin lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am J Epidemiol. 2015;181:406–421.
   PubMed Web of Science ®Google Scholar
• Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33:197–207.
   PubMed Web of Science ®Google Scholar
• Youinou P, Pers J-O, Gershwin ME, et al. Geo-epidemiology and autoimmunity. J Autoimmun. 2010;34:J163–J167.
   PubMed Web of Science ®Google Scholar
• Ansell P, Simpson J, Lightfoot T, et al. Non-hodgkin lymphoma and autoimmunity: does gender matter? Int J Cancer. 2011;129:460–466.
   PubMed Web of Science ®Google Scholar
• Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35:347–369.
   PubMed Web of Science ®Google Scholar
• Engels EA, Parsons R, Besson C, et al. Comprehensive evaluation of medical conditions associated with risk of non-hodgkin lymphoma using medicare claims (“MedWAS”). Cancer Epidemiol Biomarkers Prev. 2016;25:1105–1113.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the interlymph non-hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:15–25.
   PubMedGoogle Scholar
• Hemminki K, Liu X, Ji J, et al. Origin of B-cell neoplasms in autoimmune disease. PloS One. 2016;11:e0158360.
   PubMed Web of Science ®Google Scholar
• Kleinstern G, Maurer MJ, Liebow M, et al. History of autoimmune conditions and lymphoma prognosis. Blood Cancer J. 2018;8:73.
   PubMed Web of Science ®Google Scholar
• Kleinstern G, Averbuch M, Abu Seir R, et al. Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma. Hematol Oncol. 2018;36:457–462.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Backlin C, Iliadou A, et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum. 2006;54:3774–3781.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Endo JO, Puumala SE, et al. Prospective study of survival outcomes in non-Hodgkin’s lymphoma patients with rheumatoid arthritis. Jco. 2006;24:1597–1602.
   PubMed Web of Science ®Google Scholar
• Simard JF, Baecklund F, Chang ET, et al. Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. Int J Cancer. 2013;132:2659–2666.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Jco. 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022.
   PubMed Web of Science ®Google Scholar
• Koff JL, Rai A, Flowers CR. Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER-medicare cohort. Clin Lymphoma Myeloma Leuk. 2018;18:e115–e121.
   PubMed Web of Science ®Google Scholar
• Horesh N, Horowitz NA. Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5:e0038.
   PubMedGoogle Scholar
• Sarkozy C, Mounier N, Delmer A, et al. Impact of BMI and gender on outcomes in DLBCL patients treated with R-CHOP: a pooled study from the LYSA. Lymphoma. 2014;2014:1–12.
   Google Scholar
• Hedström G, Peterson S, Berglund M, et al. Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study. Acta Oncol. 2015;54:924–932.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Muller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640–646.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11:229.
   PubMed Web of Science ®Google Scholar
• Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25:727–734.
   PubMed Web of Science ®Google Scholar
• Gazitt T, Loughran TP. Chronic neutropenia in LGL leukemia and rheumatoid arthritis. Hematology Am Soc Hematol Educ Program. 2017;2017:181–186.
   PubMed Web of Science ®Google Scholar
• Zheng P, Chang X, Lu Q, et al. Cytopenia and autoimmune diseases: a vicious cycle fueled by mTOR dysregulation in hematopoietic stem cells. J Autoimmun. 2013;41:182–187.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Paterson C, Gilmour A, et al. Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome. RMD Open. 2018;4:e000739.
   PubMed Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–87.
   PubMedGoogle Scholar
• Shih Y-H, Yang Y, Chang K-H, et al. Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. Int J Rheum Dis. 2018;21:93–101.
   PubMed Web of Science ®Google Scholar
• Bjoro T, Holmen J, Krüger O, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol. 2000;143:639–647.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44:S41–S47.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WWL, et al. addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell–like and non–germinal center B-cell–like subtypes of diffuse large B-cell lymphoma. Jco. 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Löfström B, Backlin C, Sundström C, et al. A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis. 2007;66:1627–1632.
   PubMed Web of Science ®Google Scholar